Positive correlation between PEDF expression levels and macrophage density in the human prostate

Prostate

Volumn 73, Issue 5, 2013, Pages 549-561

  Nelius, Thomas ^a   Samathanam, Christina ^b   Martinez Marin, Dalia ^a   Gaines, Natalie ^a   Stevens, Jessica ^a   Hickson, Johnny ^a   De Riese, Werner ^a   Filleur, Stéphanie ^a,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

CD68; iNOS; M1 macrophages; PEDF; prostate gland

Indexed keywords

CD68 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; MESSENGER RNA; PIGMENT EPITHELIUM DERIVED FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL INFILTRATION; CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE SIZE; PROSTATITIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; EYE PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; MACROPHAGES; MALE; MICE; MONOCYTES; NEOPLASM GRADING; NERVE GROWTH FACTORS; PROSTATE; PROSTATIC NEOPLASMS; PROSTATITIS; RETROSPECTIVE STUDIES; RNA, MESSENGER; SERPINS;

EID: 84875223290     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22595     Document Type: Article

References (57)

1. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG,. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7 (4): 256-269.
2. Wang W, Bergh A, Damber JE,. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate. Prostate 2009; 69 (13): 1378-1386.
3. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S,. The influence of chronic inflammation in prostatic carcinogenesis: A 5-year followup study. J Urol 2006; 176 (3): 1012-1016.
4. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ,. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005; 97 (13): 975-980.
5. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG,. Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis 2005; 26 (7): 1170-1181.
6. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB,. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 2005; 14 (2): 390-396.
7. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, Zhang J,. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 2007; 67 (8): 3646-3653.
8. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D,. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87 (8): 3336-3343.
9. Savarese DM, Valinski H, Quesenberry P, Savarese T,. Expression and function of colony-stimulating factors and their receptors in human prostate carcinoma cell lines. Prostate 1998; 34 (2): 80-91.
10. Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A,. Tumor associated macrophages in human prostate cancer: Relation to clinicopathological variables and survival. Int J Oncol 2000; 17 (3): 445-451.
11. Shimura S, Yang G, Ebara S, Wheeler TM, Frolov A, Thompson TC,. Reduced infiltration of tumor-associated macrophages in human prostate cancer: Association with cancer progression. Cancer Res 2000; 60 (20): 5857-5861.
12. Vukanovic J, Isaacs JT,. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995; 55 (7): 1499-1504.
13. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D,. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: Role of anti-inflammatory activity. J Bone Miner Res 2007; 22 (Suppl. 2): V74-V80.
14. Nonn L, Duong D, Peehl DM,. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 2007; 28 (6): 1188-1196.
15. Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikstrom P, Bergh A,. Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia (New York, NY) 2010; 12 (4): 336-345.
16. Zhu P, Baek SH, Bourk EM, Ohgi KA, Garcia-Bassets I, Sanjo H, Akira S, Kotol PF, Glass CK, Rosenfeld MG, Rose DW,. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 2006; 124 (3): 615-629.
17. Filleur S, Nelius T, de Riese W, Kennedy RC,. Characterization of PEDF: A multi-functional serpin family protein. J Cell Biochem 2009; 106 (5): 769-775.
18. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE,. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003; 9 (6): 774-780.
19. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE, Bergh A,. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004; 64 (16): 5664-5671.
20. Takanohashi A, Yabe T, Schwartz JP,. Pigment epithelium-derived factor induces the production of chemokines by rat microglia. Glia 2005; 51 (4): 266-278.
21. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX,. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20 (2): 323-325.
22. Sanagi T, Yabe T, Yamada H,. The regulation of pro-inflammatory gene expression induced by pigment epithelium-derived factor in rat cultured microglial cells. Neurosci Lett 2005; 380 (1-2): 105-110.
23. Yoshida Y, Yamagishi SI, Matsui T, Nakamura K, Imaizumi T, Yoshimura K, Yamakawa R,. Elevated levels of pigment epithelium-derived factor (PEDF) in aqueous humor of patients with uveitis. Br J Ophthalmol 2006; 91 (2): 149-150.
24. Eichler W, Yafai Y, Wiedemann P, Fengler D,. Antineovascular agents in the treatment of eye diseases. Curr Pharm Des 2006; 12 (21): 2645-2660.
25. Jenkins AJ, Zhang SX, Rowley KG, Karschimkus CS, Nelson CL, Chung JS, O'Neal DN, Januszewski AS, Croft KD, Mori TA, Dragicevic G, Harper CA, Best JD, Lyons TJ, Ma JX,. Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med 2007; 24 (12): 1345-1351.
26. Park K, Jin J, Hu Y, Zhou K, Ma JX,. Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. Am J Pathol 2011; 178 (2): 688-698.
27. Ueda S, Yamagishi S, Matsui T, Jinnouchi Y, Imaizumi T,. Administration of pigment epithelium-derived factor inhibits left ventricular remodeling and improves cardiac function in rats with acute myocardial infarction. Am J Pathol 2011; 178 (2): 591-598.
28. Hirsch J, Johnson CL, Nelius T, Kennedy R, Riese W, Filleur S,. PEDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFkappaB and PPARgamma. Cytokine 2011; 55 (2): 202-210.
29. Yamagishi S, Matsui T, Nakamura K, Yoshida T, Shimizu K, Takegami Y, Shimizu T, Inoue H, Imaizumi T,. Pigment-epithelium-derived factor (PEDF) inhibits angiotensin-II-induced vascular endothelial growth factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 2006; 71 (3): 222-226.
30. Yamagishi SI, Kikuchi S, Nakamura K, Matsui T, Makino T, Norisugi O, Shimizu T, Inoue H, Imaizumi T,. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1. Horm Metab Res 2006; 38 (8): 546-548.
31. Zamiri P, Masli S, Streilein JW, Taylor AW,. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006; 47 (9): 3912-3918.
32. Ho TC, Chen SL, Shih SC, Chang SJ, Yang SL, Hsieh JW, Cheng HC, Chen LJ, Tsao YP,. Pigment epithelium-derived factor (PEDF) promotes tumor cell death by inducing macrophage membrane tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2011; 286 (41): 35943-35954.
33. Nelius T, Gaines N, Rinard K, Lopez J, Sennoune S, Cobos E, Filleur S,. PEDF expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. In preparation. 2012.
34. von Knethen A, Brune B,. PKC alpha depletion in RAW264.7 macrophages following microbial/IFNgamma stimulation is PC-PLC-mediated. Antioxid Redox Signal 2005; 7 (9-10): 1217-1222.
35. Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV,. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005; 65 (12): 5144-5152.
36. Tombran-Tink J, Mazuruk K, Rodriguez IR, Chung D, Linker T, Englander E, Chader GJ,. Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Mol Vis 1996; 2: 11.
37. Browne M, Stellmach V, Cornwell M, Chung C, Doll JA, Lee EJ, Jameson JL, Reynolds M, Superina RA, Abramson LP, Crawford SE,. Gene transfer of pigment epithelium-derived factor suppresses tumor growth and angiogenesis in a hepatoblastoma xenograft model. Pediatr Res 2006; 60 (3): 282-287.
38. Tuxhorn JA, Ayala GE, Rowley DR,. Reactive stroma in prostate cancer progression. J Urol 2001; 166 (6): 2472-2483.
39. Wagsater D, Lofgren S, Zar N, Hugander A, Dimberg J,. Pigment epithelium-derived factor expression in colorectal cancer patients. Cancer Invest 2010; 28 (8): 872-877.
40. Zhou D, Cheng SQ, Ji HF, Wang JS, Xu HT, Zhang GQ, Pang D,. Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol 2010; 136 (11): 1719-1727.
41. Chen J, Ye L, Zhang L, Jiang WG,. The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol 2009; 35 (1): 159-166.
42. Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG,. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int J Mol Med 2006; 17 (5): 937-944.
43. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, Murakami Y, Hase R, Takahashi R, Mega S, Shichinohe T, Kawarada Y, Itoh T, Okushiba S, Kondo S, Katoh H,. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004; 64 (10): 3533-3537.
44. Qingyi Z, Lin Y, Junhong W, Jian S, Weizhou H, Long M, Zeyu S, Xiaojian G,. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: A differential proteomics approach. Cancer Invest 2009; 27 (7): 794-801.
45. Jiang Z, Fang Z, Ding Q,. Prognostic role of pigment epithelium-derived factor in clear cell renal cell carcinoma. Urol Int 2010; 84 (3): 334-340.
46. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA,. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer 2008; 15 (4): 1069-1074.
47. Zhang BC, Gao J, Wang J, Rao ZG, Wang BC, Gao JF,. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol (Northwood, London, England) 2011; 28 (4): 1447-1452.
48. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ,. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 2011; 11 (1): 91-100.
49. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana M, Suzuki N, Inoue M, Soma G, Nagasue N,. The degree of macrophage infiltration into the cancer cell nest is a significant predictor of survival in gastric cancer patients. Anticancer Res 2003; 23 (6D): 5015-5022.
50. Ma J, Liu L, Che G, Yu N, Dai F, You Z,. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010; 10: 112.
51. Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, Ding Y, Zhou QM, Zhang X, Pang ZZ, Wan DS, Zeng YX, Zhang XS,. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med 2010; 8: 13.
52. Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M, Nagahara A, Aozasa K, Tsujimura A,. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int 2011; 107 (12): 1918-1922.
53. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A,. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18 (5): 349-355.
54. Coulter JA, Page NL, Worthington J, Robson T, Hirst DG, McCarthy HO,. Transcriptional regulation of inducible nitric oxide synthase gene therapy: Targeting early stage and advanced prostate cancer. J Gene Med 2010; 12 (9): 755-765.
55. McCarthy HO, Coulter JA, Worthington J, Robson T, Hirst DG,. Human osteocalcin: A strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer. J Gene Med 2007; 9 (6): 511-520.
56. Adams C, McCarthy HO, Coulter JA, Worthington J, Murphy C, Robson T, Hirst DG,. Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells. J Gene Med 2009; 11 (2): 160-168.
57. Olson MV, Lee J, Zhang F, Wang A, Dong Z,. Inducible nitric oxide synthase activity is essential for inhibition of prostatic tumor growth by interferon-beta gene therapy. Cancer Gene Ther 2006; 13 (7): 676-685.